Form 13-F position report

CERO THERAPEUTICS HLDGS INC

Reported by WOLVERINE ASSET MANAGEMENT LLC

CEROW CUSIP 71902K113 Manager CIK 0001279891

Reported 0 shares, down 33,796 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 17 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 33000
2022-03-31 17000
2022-06-30 8000
2022-09-30 6000
2022-12-31 3788
2023-03-31 3524
2023-06-30 5370
2023-09-30 6293
2023-12-31 2065
2024-03-31 4372
2024-06-30 880
2024-09-30 223
2024-12-31 363
2025-03-31 635
2025-06-30 804
2025-09-30 449
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for CERO THERAPEUTICS HLDGS INC held by WOLVERINE ASSET MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -33,796 (-100.0%) 0 $0 2026-02-02
Q3 2025 Unchanged 33,796 0 (0.0%) < 0.01% $449 2025-10-28
Q2 2025 Reduced 33,796 -10,000 (-22.8%) < 0.01% $804 2025-08-04
Q1 2025 Unchanged 43,796 0 (0.0%) < 0.01% $635 2025-05-12
Q4 2024 Unchanged 43,796 0 (0.0%) < 0.01% $363 2025-02-03
Q3 2024 Unchanged 43,796 0 (0.0%) < 0.01% $223 2024-11-04
Q2 2024 Reduced 43,796 -20,317 (-31.7%) < 0.01% $880 2024-08-01
Q1 2024 Reduced 64,113 -23,780 (-27.1%) < 0.01% $4,372 2024-05-13
Q4 2023 Unchanged 87,893 0 (0.0%) < 0.01% $2,065 2024-02-01
Q3 2023 Unchanged 87,893 0 (0.0%) < 0.01% $6,293 2023-11-13
Q2 2023 Unchanged 87,893 0 (0.0%) < 0.01% $5,370 2023-08-07
Q1 2023 Unchanged 87,893 0 (0.0%) < 0.01% $3,524 2023-05-08
Q4 2022 Added 87,893 +7,204 (8.9%) < 0.01% $3,788 2023-02-01
Q3 2022 Unchanged 80,689 0 (0.0%) < 0.01% $6,000 2022-11-10
Q2 2022 Unchanged 80,689 0 (0.0%) < 0.01% $8,000 2022-08-03
Q1 2022 Unchanged 80,689 0 (0.0%) < 0.01% $17,000 2022-05-04
Q4 2021 New 80,689 +80,689 (0.0%) < 0.01% $33,000 2022-02-09

Who else reported the position

21 managers reported CERO THERAPEUTICS HLDGS INC for Q4 2025.

Managers reporting CERO THERAPEUTICS HLDGS INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Ancora Advisors LLC Unchanged 2,500 0 < 0.01% $22 15 qtrs
Clear Street Group Inc Reduced 0 -461,653 0 $0 2 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 0 -98,468 0 $0 4 qtrs
Context Capital Management LLC Reduced 0 -122,013 0 $0 16 qtrs
Calamos Advisors LLC Reduced 0 -12,500 0 $0 14 qtrs
Virtu Financial LLC Reduced 0 -21,104 0 $0 3 qtrs
Q Global Advisors LLC Reduced 0 -170,785 0 $0 4 qtrs
Saba Capital Management L P Reduced 0 -295,913 0 $0 17 qtrs
Blue Owl Capital Holdings LP Reduced 0 -224,930 0 $0 6 qtrs
WHITEBOX ADVISORS LLC Reduced 0 -23,250 0 $0 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 02, 2026
Filing type
13F-HR
Position type
*W EXP 02/13/202

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.